Annales De Dermatologie Et De Venereologie最新文献

英文中文

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients 晚期默克尔细胞癌患者的生存结局和对免疫检查点抑制剂的反应：一项81例患者的回顾性研究

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-08-02 DOI: 10.1016/j.annder.2025.103411

C. David , C. Coquelle , Y. Le Corre , J.-M. L’Orphelin , C. Nardin , F. Aubin , J. Cassecuel , B. Dreno , E. Wierzbiecka-Hainault , G. Bens , N. Beneton , M. Dinulescu , T. Kervarrec , P. Saiag , A. Blom , M. Samimi

Background

Advanced Merkel cell carcinoma (MCC) has been shown to be effectively targeted by PD-1/PD-L1 inhibitors in phase II trials and real-world studies. More than 50% of MCC patients display resistance to PD-1/PD-L1 inhibitors while identification of predictive factors for response has been inconclusive so far in this population. Our primary objective was to assess overall survival (OS) in a real-world cohort of advanced MCC patients treated with PD(L)1 inhibitors in France. Secondary objectives were to assess real-world overall response rates (rwORR), duration of response (rwDOR), progression-free survival (rwPFS) and predictive factors of response.

Methods

Patients from an ongoing cohort of MCC cases (1998–2023) were included in the current study if they had received at least one infusion of PD-1/PD-L1 inhibitor for advanced MCC as any line of treatment.

Results

Among the 81 patients included, OS at 24 months- was 58 % (95 % confidence interval (CI) 46.2–68.9). RwORR was 51.9 % (95 %CI 40.9–62.9). Median OS was significantly higher among responders than non-responders (median OS 59.0 months (95 %CI 39.4-not reached (NR)) vs. 8.1 months (95 %CI 6.6–17.0). RwDOR was significantly shorter in partial vs. complete responders (3.4 months vs. NR). Patients with rwDOR in excess of 6 months had improved OS compared to others (median OS: 59.0 months, 95 %CI 39-NR vs. 28.5 months, 95 %CI 20.3-NR). Median rwPFS was 9.0 months (95 %CI 4.5–20.4). None of the baseline clinical and laboratory characteristics or treatment-related characteristics were found to be associated with response.

Conclusion

Our results confirm durable responses and prolonged survival to PD-1/PD-L1 inhibitors in MCC patients. We did not identify any biomarker predictive of response to treatment. Our data underline the benefit of achieving complete response in PD(L)1 inhibitor-treated MCC patients, allowing longer duration of response and increased OS, suggesting the potential use of DOR above 6 months as a surrogate marker of OS in this setting.

在II期试验和现实世界的研究中，PD-1/PD-L1抑制剂已被证明可有效靶向晚期默克尔细胞癌（MCC）。超过50%的MCC患者对PD-1/PD-L1抑制剂表现出耐药性，而迄今为止，在这一人群中，对反应的预测因素的鉴定尚无定论。我们的主要目标是评估在法国接受PD(L)1抑制剂治疗的晚期MCC患者的实际队列的总生存期（OS）。次要目标是评估真实世界的总缓解率（rwORR）、缓解持续时间（rwDOR）、无进展生存期（rwPFS）和反应的预测因素。方法正在进行的MCC病例队列（1998-2023）中，如果患者接受了至少一次PD-1/PD-L1抑制剂输注作为任何一种治疗方法，则将其纳入本研究。结果在纳入的81例患者中，24 个月时的OS为58 %（95 %可信区间（CI） 46.2-68.9）。RwORR为51.9 %（95 %CI 40.9-62.9）。应答者的中位生存期明显高于无应答者(中位生存期59.0 个月（95 %CI 39.4-未达到（NR）） vs. 8.1 个月（95 %CI 6.6-17.0）。部分缓解者的RwDOR明显短于完全缓解者（3.4 个月vs NR）。rwDOR超过6 个月的患者与其他患者相比，OS得到改善（中位OS: 59.0 个月，95% %CI 39-NR对28.5 个月，95 %CI 20.3-NR）。中位rwPFS为9.0 个月（95 %CI 4.5-20.4）。没有发现基线临床和实验室特征或治疗相关特征与反应相关。结论：我们的研究结果证实了PD-1/PD-L1抑制剂对MCC患者的持久疗效和延长的生存期。我们没有发现任何预测治疗反应的生物标志物。我们的数据强调了PD(L)1抑制剂治疗的MCC患者实现完全缓解的益处，允许更长的缓解持续时间和增加的OS，这表明在这种情况下，DOR超过6 个月作为OS的替代指标的潜在用途。

{"title":"Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients","authors":"C. David , C. Coquelle , Y. Le Corre , J.-M. L’Orphelin , C. Nardin , F. Aubin , J. Cassecuel , B. Dreno , E. Wierzbiecka-Hainault , G. Bens , N. Beneton , M. Dinulescu , T. Kervarrec , P. Saiag , A. Blom , M. Samimi","doi":"10.1016/j.annder.2025.103411","DOIUrl":"10.1016/j.annder.2025.103411","url":null,"abstract":"<div><h3>Background</h3><div>Advanced Merkel cell carcinoma (MCC) has been shown to be effectively targeted by PD-1/PD-L1 inhibitors in phase II trials and real-world studies. More than 50% of MCC patients display resistance to PD-1/PD-L1 inhibitors while identification of predictive factors for response has been inconclusive so far in this population. Our primary objective was to assess overall survival (OS) in a real-world cohort of advanced MCC patients treated with PD(L)1 inhibitors in France. Secondary objectives were to assess real-world overall response rates (rwORR), duration of response (rwDOR), progression-free survival (rwPFS) and predictive factors of response.</div></div><div><h3>Methods</h3><div>Patients from an ongoing cohort of MCC cases (1998–2023) were included in the current study if they had received at least one infusion of PD-1/PD-L1 inhibitor for advanced MCC as any line of treatment.</div></div><div><h3>Results</h3><div>Among the 81 patients included, OS at 24 months- was 58 % (95 % confidence interval (CI) 46.2–68.9). RwORR was 51.9 % (95 %CI 40.9–62.9). Median OS was significantly higher among responders than non-responders (median OS 59.0 months (95 %CI 39.4-not reached (NR)) vs. 8.1 months (95 %CI 6.6–17.0). RwDOR was significantly shorter in partial vs. complete responders (3.4 months vs. NR). Patients with rwDOR in excess of 6 months had improved OS compared to others (median OS: 59.0 months, 95 %CI 39-NR vs. 28.5 months, 95 %CI 20.3-NR). Median rwPFS was 9.0 months (95 %CI 4.5–20.4). None of the baseline clinical and laboratory characteristics or treatment-related characteristics were found to be associated with response.</div></div><div><h3>Conclusion</h3><div>Our results confirm durable responses and prolonged survival to PD-1/PD-L1 inhibitors in MCC patients. We did not identify any biomarker predictive of response to treatment. Our data underline the benefit of achieving complete response in PD(L)1 inhibitor-treated MCC patients, allowing longer duration of response and increased OS, suggesting the potential use of DOR above 6 months as a surrogate marker of OS in this setting.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 3","pages":"Article 103411"},"PeriodicalIF":2.8,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study 一项多中心实用随机对照试验，比较50%水杨酸、液氮、5% 5-氟尿嘧啶乳膏和5%咪喹莫特乳膏对先前治疗过的足底疣的疗效。vaie （VeRrues plAntaIres en villE）研究

IF 2.8 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-07-30 DOI: 10.1016/j.annder.2025.103406

J. Chanal , F. Aubin , I. Buffière , C. Perrière , H. Bocquet , A. Aubin , Y. Farcet , C. Ludmann , A. Duboz , J. Marco-Bonnet , C. Maury , C. Tremeau-Martinage , A-M. Hubert-Asso , D. Coustou , A-M. Heudes , M. Kemula , M. Beylot-Barry , F. Tétart , A. Eche-Dejoie , A-M. Duvochel , O. Chosidow

Background

Plantar warts are common among the general population. After failure of first-line treatment, they are challenging to treat.

Objectives

To compare 4 second-line treatments — 50 % salicylic acid ointment (SA) under occlusion, liquid nitrogen, 5 % 5-fluorouracil (5-FU) cream under occlusion, and 5 % imiquimod cream — in terms of complete remission after 90 days.

Methods

A multicentre, pragmatic, randomized, controlled trial. Screened patients with plantar warts were initially treated with a 5-week regimen of SA, followed by a 1-week washout period. Patients exhibiting treatment failure were randomly assigned to one of five treatments, with the allocation ratio fixed at 1:1:1:1:1. The fifth arm, treated with duct tape, was withdrawn during the study. We aimed to enrol 436 patients (109 in each treatment), but based on an anticipated response rate of 33 % in the pre-inclusion period, the target enrolment figure was increased to 660. An ancillary study (BIOVRAIE) was planned to analyse wart genotypes. The trial was registered on ClinicalTrials.gov (NCT 01059110).

Results

A total of 358 patients (54 % of the target) were enrolled in the pre-inclusion period; 140 patients achieved complete remission during this period and 174 were included. Myrmecia warts constituted the most prevalent form of plantar warts (83.9 %), followed by mosaic warts (13.2 %) and a combination of both (2.8 %). Human papilloma virus (HPV) 27 and HPV1 infection were predominant (90 % and 84 %, respectively). At inclusion, 22 patients were assigned to the duct tape arm before its withdrawal, 41 to SA, 36 to cryotherapy, 33 to 5-FU, and 42 to imiquimod. On Day 90, 6 (20 %) patients in the SA group were in complete remission, as well as 3 (11 %) in the cryotherapy group, 1 (3.5 %) in the 5-FU group, 2 (6.6 %) in the imiquimod group.

Conclusions

While the trial failed to enrol the planned number of patients, the study showed that no treatment had a substantial positive effect as second-line treatment of plantar warts.

背景足底疣在普通人群中很常见。在一线治疗失败后，他们是具有挑战性的治疗。目的比较4种二线治疗——阻断下50% %水杨酸软膏（SA）、液氮、阻断下5% % 5-氟尿嘧啶（5- fu）乳膏和5% %咪喹莫特乳膏——90 天后完全缓解的情况。方法采用多中心、实用、随机、对照试验。筛选的足底疣患者最初接受5周的SA治疗，随后是1周的洗脱期。治疗失败的患者随机分配到5种治疗方案中的一种，分配比例固定为1:1:1:1:1。在研究期间，用管道胶带治疗的第五组被撤回。我们的目标是纳入436例患者（每种治疗109例），但基于预纳入期的预期缓解率为33. %，目标入组人数增加到660例。一项辅助研究（biovaire）计划分析疣基因型。该试验已在ClinicalTrials.gov （NCT 01059110）上注册。结果预纳入期共入组358例患者（54. %）；140例患者在此期间达到完全缓解，其中174例纳入研究。桃金娘疣是足底疣最常见的形式（83.9 %），其次是马赛克疣（13.2 %）和两者的组合（2.8 %）。人乳头瘤病毒（HPV） 27和人乳头瘤病毒（HPV） 1感染占主导地位（分别为90 %和84 %）。纳入时，22名患者在停药前被分配到管道胶带臂，41名患者接受SA治疗，36名患者接受冷冻治疗，33名患者接受5-FU治疗，42名患者接受咪喹莫特治疗。第90天，SA组6例（20 %）患者完全缓解，冷冻治疗组3例（11 %），5-FU组1例（3.5 %），咪喹莫特组2例（6.6 %）。虽然该试验未能招募到计划数量的患者，但研究表明，作为足底疣的二线治疗，没有一种治疗方法具有实质性的积极效果。

{"title":"A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study","authors":"J. Chanal , F. Aubin , I. Buffière , C. Perrière , H. Bocquet , A. Aubin , Y. Farcet , C. Ludmann , A. Duboz , J. Marco-Bonnet , C. Maury , C. Tremeau-Martinage , A-M. Hubert-Asso , D. Coustou , A-M. Heudes , M. Kemula , M. Beylot-Barry , F. Tétart , A. Eche-Dejoie , A-M. Duvochel , O. Chosidow","doi":"10.1016/j.annder.2025.103406","DOIUrl":"10.1016/j.annder.2025.103406","url":null,"abstract":"<div><h3>Background</h3><div>Plantar warts are common among the general population. After failure of first-line treatment, they are challenging to treat.</div></div><div><h3>Objectives</h3><div>To compare 4 second-line treatments — 50 % salicylic acid ointment (SA) under occlusion, liquid nitrogen, 5 % 5-fluorouracil (5-FU) cream under occlusion, and 5 % imiquimod cream — in terms of complete remission after 90 days.</div></div><div><h3>Methods</h3><div>A multicentre, pragmatic, randomized, controlled trial. Screened patients with plantar warts were initially treated with a 5-week regimen of SA, followed by a 1-week washout period. Patients exhibiting treatment failure were randomly assigned to one of five treatments, with the allocation ratio fixed at 1:1:1:1:1. The fifth arm, treated with duct tape, was withdrawn during the study. We aimed to enrol 436 patients (109 in each treatment), but based on an anticipated response rate of 33 % in the pre-inclusion period, the target enrolment figure was increased to 660. An ancillary study (BIOVRAIE) was planned to analyse wart genotypes. The trial was registered on <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (NCT 01059110).</div></div><div><h3>Results</h3><div>A total of 358 patients (54 % of the target) were enrolled in the pre-inclusion period; 140 patients achieved complete remission during this period and 174 were included. Myrmecia warts constituted the most prevalent form of plantar warts (83.9 %), followed by mosaic warts (13.2 %) and a combination of both (2.8 %). Human papilloma virus (HPV) 27 and HPV1 infection were predominant (90 % and 84 %, respectively). At inclusion, 22 patients were assigned to the duct tape arm before its withdrawal, 41 to SA, 36 to cryotherapy, 33 to 5-FU, and 42 to imiquimod. On Day 90, 6 (20 %) patients in the SA group were in complete remission, as well as 3 (11 %) in the cryotherapy group, 1 (3.5 %) in the 5-FU group, 2 (6.6 %) in the imiquimod group.</div></div><div><h3>Conclusions</h3><div>While the trial failed to enrol the planned number of patients, the study showed that no treatment had a substantial positive effect as second-line treatment of plantar warts.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 3","pages":"Article 103406"},"PeriodicalIF":2.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144739283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Malignant syphilis: a rare presentation of a re-emerging disease 恶性梅毒：一种罕见的再次出现的疾病

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-07-08 DOI: 10.1016/j.annder.2025.103380

A. Le Guern, J.-F. Quinchon, M. Bataille, D. Lebas, P. Modiano

引用次数: 0

Henri Édouard Schedel (1804–1856): his life and contribution to the study of scabies 亨利Édouard舍德尔（1804-1856）：他的一生和对疥疮研究的贡献

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-06-06 DOI: 10.1016/j.annder.2025.103392

I. Dimitriadis, M. Karamanou, J. Chevallier, T.G. Papaioannou, S.N. Michaleas

引用次数: 0

Familial facial discoid dermatosis 家族性面部盘状皮肤病

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-06-03 DOI: 10.1016/j.annder.2025.103385

I. Moulonguet, B. Matard

引用次数: 0

Mycoplasma-induced rash and mucositis (MIRM): Insights from four cases 支原体引起的皮疹和粘膜炎（MIRM）：从四个病例的见解

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-06-03 DOI: 10.1016/j.annder.2025.103387

J. Kaikati, J. Abou Khater, H. Traineau, C. Lheure, A. Dangien, S. Aractingi, N. Dupin

引用次数: 0

Strong propensity to accept a diagnosis via tele-expertise in dermatology: A nationwide analysis 接受皮肤科远程专家诊断的强烈倾向：一项全国性分析

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-06-03 DOI: 10.1016/j.annder.2025.103388

B. Cribier , N. Perez Cullel , C. Baissac , Y. Ben Hayound , B. Halioua , C. Taieb , M. Saint Aroman

引用次数: 0

Angiolymphoid hyperplasia with eosinophilia treated with dupilumab in a biologic-naïve patient dupilumab治疗biologic-naïve患者血管淋巴样增生伴嗜酸性粒细胞增多症

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-06-03 DOI: 10.1016/j.annder.2025.103390

M.F. Ortiz-Nuño, J.A. Esquivel-Valerio, J.A. García-Lozano, D.A. Galarza-Delgado, J.A. Cardenas-de la Garza

引用次数: 0

Development of linear IgA bullous dermatosis in a patient during an exacerbation of psoriasis 银屑病加重期间患者线状IgA大疱性皮肤病的发展

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-06-03 DOI: 10.1016/j.annder.2025.103386

C. Ji, Y. Lv, Y. Li, R. Chen, W. Hu

引用次数: 0

Eruptive pyogenic granulomas of the proximal nail folds as a complication of cast immobilization 近端甲襞爆发性化脓性肉芽肿作为石膏固定的并发症

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-05-24 DOI: 10.1016/j.annder.2025.103384

M. Aboudourib, O. Khadiri, M. Abid, O. Hocar, S. Amal

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀